Stock Updates

How has BioMarin Pharmaceutical Inc.:(NASDAQ:BMRN) performed recently?

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a large market cap stock with a market cap of 12392.67. It is in the Biotechnology industry and sector Healthcare, with a current P/E of *TBA, a forward P/E of *TBA and EPS of -1.18. At a stock price of 79.86 (-1.87%) it has a dividend yield of *TBA.

EPS growth for the last five years have been -21.30%, more recently this last year it has grown by -17.30%. The next year growth is going to be about 54.00% and more long-term 25.00% after five years. EPS growth quarter over quarter is -23.10%. Sales growth for the past five years have been 18.80% and sales growth quarter over quarter is 16.70%.

For performance, BioMarin Pharmaceutical Inc. the past week has seen a gain of 7.04%. For the last month performance for BioMarin Pharmaceutical Inc. is -11.27%. While the last quarter is -3.81% and half year, -23.88%. Finally for the year, performance is -41.64%.

The 52-week high for BioMarin Pharmaceutical Inc., is at -47.37%, and for the 52-week low it comes to a value of 28.56%. The 20-day simple moving average is -5.40% and -12.90% for the 200-day simple moving average.

Volatility for the week is at 4.22%, and for the month it is 4.45%. BioMarin Pharmaceutical Inc., has a target price of 111.95.

In terms of debt, long term debt/equity is 0.29, and for total debt/equity BioMarin Pharmaceutical Inc. has 0.29. The gross margin is 82.40%, while operating margin is -13.60%, the profit margin is -20.50%. The current ratio is 2.6 and the quick ratio is 1.8.

Insider ownership is at 0.60%, with instituitional ownership at 100.00%. BioMarin Pharmaceutical Inc. has a payout ratio of *TBA. With the total shares outstanding coming to 155.18. The shares float is 155.18, with the float short at 3.67%, with short ratio coming to 3.86.

In terms of returns, the return on assets see BioMarin Pharmaceutical Inc., get -5.20%, with its returns on investment at -4.20%. Return on equity is -8.10%. So will the investors see the target price of 111.95, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Stephen Butters

Leave a Comment